Rabies vaccine

Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.

A Phase IIb trial of the RH5.1/Matrix-M vaccine shows 55% efficacy in preventing clinical malaria over six months in young children.

AIM Vaccine Co., Ltd. has pre-applied for marketing approval of its serum-free rabies vaccine, which showed excellent safety and immunogenicity in Phase III trials.

A phase 2b trial in Burkina Faso demonstrates the RH5.1/Matrix-M malaria vaccine's safety and efficacy, showing a 55% vaccine efficacy in a delayed third-dose regimen among children aged 5-17 months.